Total Payments
$40,292
2024 Payments
$801.36
Companies
52
Transactions
683
Medicare Patients
10,471
Medicare Billing
$480,580
Payment Breakdown by Category
Research$27,207 (67.5%)
Food & Beverage$10,226 (25.4%)
Travel$2,802 (7.0%)
Education$36.50 (0.1%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27,207 | 15 | 67.5% |
| Food and Beverage | $10,226 | 659 | 25.4% |
| Travel and Lodging | $2,802 | 6 | 7.0% |
| Education | $36.50 | 2 | 0.1% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$27,207
15 transactions
General
$13,085
668 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $24,412 | 5 | $0 (2023) |
| Seqirus USA Inc | $2,049 | 7 | $0 (2019) |
| Shionogi Inc | $1,737 | 8 | $0 (2017) |
| Novavax Inc | $1,552 | 4 | $0 (2023) |
| Novo Nordisk Inc | $1,541 | 125 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,454 | 94 | $0 (2024) |
| ABBVIE INC. | $1,189 | 89 | $0 (2024) |
| GlaxoSmithKline, LLC. | $955.76 | 21 | $0 (2024) |
| Allergan, Inc. | $687.60 | 53 | $0 (2020) |
| Becton, Dickinson and Company | $540.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $801.36 | 50 | Novo Nordisk Inc ($208.82) |
| 2023 | $5,637 | 83 | Eli Lilly and Company ($2,299) |
| 2022 | $7,021 | 85 | Eli Lilly and Company ($5,799) |
| 2021 | $17,518 | 91 | Eli Lilly and Company ($16,314) |
| 2020 | $882.73 | 66 | Novo Nordisk Inc ($201.99) |
| 2019 | $1,595 | 86 | Seqirus USA Inc ($420.57) |
| 2018 | $3,121 | 118 | Seqirus USA Inc ($1,629) |
| 2017 | $3,716 | 104 | Shionogi Inc ($1,737) |
All Payment Transactions
683 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: RESPIRATORY | ||||||
| 11/18/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $8.25 | General |
| Category: Diabetes | ||||||
| 11/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX, BEXSERO | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: RESPIRATORY | ||||||
| 10/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $14.48 | General |
| Category: NEUROLOGY | ||||||
| 10/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.69 | General |
| Category: PSYCHIATRY | ||||||
| 10/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.51 | General |
| 10/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.69 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: PAIN | ||||||
| 09/18/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: Diabetes | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: PSYCHIATRY | ||||||
| 08/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: Diabetes | ||||||
| 08/16/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: RESPIRATORY | ||||||
| 08/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $10.90 | General |
| Category: Obesity | ||||||
| 08/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.84 | General |
| Category: PSYCHIATRY | ||||||
| 07/16/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: ADHD | ||||||
| 07/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: DIABETES | ||||||
| 06/27/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: Obesity | ||||||
| 06/25/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $2.71 | General |
| Category: Diabetes | ||||||
| 06/12/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Endocrinology | ||||||
| 05/29/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: NEUROSCIENCE | ||||||
| 05/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $22,113 | 4 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $2,299 | 1 |
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines | Novavax Inc | $1,552 | 4 |
| A Phase 3b, Controlled, Open Label, Multi Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline s Meningococcal ACWY Conjugate Vaccine Menveo , Administered to Healthy Individuals 15 through 55 years of age, approximate | GlaxoSmithKline, LLC. | $703.19 | 5 |
| COVID-19 | Becton, Dickinson and Company | $540.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,531 | 2,538 | $263,178 | $114,780 |
| 2022 | 19 | 1,503 | 2,302 | $241,992 | $105,877 |
| 2021 | 40 | 2,073 | 2,793 | $209,215 | $110,907 |
| 2020 | 52 | 5,364 | 7,376 | $193,852 | $149,017 |
Total Patients
10,471
Total Services
15,009
Medicare Billing
$480,580
Procedure Codes
128
All Medicare Procedures & Services
128 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 252 | 555 | $120,849 | $45,595 | 37.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 272 | 272 | $62,560 | $34,209 | 54.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 37 | 37 | $19,573 | $10,428 | 53.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 331 | 625 | $5,000 | $4,879 | 97.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 78 | 78 | $4,914 | $4,816 | 98.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 24 | 27 | $8,397 | $4,039 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 60 | $9,282 | $3,023 | 32.6% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 12 | 12 | $3,792 | $1,935 | 51.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 82 | 82 | $1,394 | $1,366 | 98.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 44 | 44 | $2,200 | $1,298 | 59.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 55 | 148 | $7,400 | $1,158 | 15.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 133 | 135 | $11,745 | $1,006 | 8.6% |
| 90471 | Administration of vaccine | Office | 2023 | 46 | 46 | $2,300 | $576.83 | 25.1% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 32 | 49 | $2,009 | $353.40 | 17.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 18 | 70 | $420.00 | $46.75 | 11.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 30 | 112 | $1,120 | $35.66 | 3.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 32 | 186 | $223.20 | $14.15 | 6.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 256 | 494 | $102,258 | $38,471 | 37.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 233 | 233 | $53,590 | $29,367 | 54.8% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 54 | 59 | $18,349 | $9,234 | 50.3% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 18 | 18 | $9,522 | $5,008 | 52.6% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 30 | 30 | $9,900 | $4,870 | 49.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 76 | 76 | $4,788 | $4,695 | 98.1% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 13 | 13 | $3,250 | $3,172 | 97.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 54 | $7,916 | $2,895 | 36.6% |
About Dr. Darrell Herrington, DO
Dr. Darrell Herrington, DO is a Family Medicine healthcare provider based in San Angelo, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154388767.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Darrell Herrington, DO has received a total of $40,292 in payments from pharmaceutical and medical device companies, with $801.36 received in 2024. These payments were reported across 683 transactions from 52 companies. The most common payment nature is "" ($27,207).
As a Medicare-enrolled provider, Herrington has provided services to 10,471 Medicare beneficiaries, totaling 15,009 services with total Medicare billing of $480,580. Data is available for 4 years (2020–2023), covering 128 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location San Angelo, TX
- Active Since 04/27/2006
- Last Updated 12/05/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1154388767
Products in Payments
- Flucelvax (Biological) $1,629
- VRAYLAR (Drug) $684.89
- Ozempic (Drug) $653.36
- BD Veritor Plus Analyzer (Device) $540.00
- SYMBICORT (Drug) $499.51
- UBRELVY (Drug) $497.29
- BREZTRI (Drug) $421.51
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) (Biological) $420.57
- JARDIANCE (Drug) $374.83
- Victoza (Drug) $318.61
- JANUVIA (Drug) $315.35
- BYSTOLIC (Drug) $247.60
- FARXIGA (Drug) $234.95
- Rybelsus (Drug) $234.82
- NURTEC ODT (Drug) $218.05
- BEVESPI AEROSPHERE (Drug) $213.51
- QULIPTA (Drug) $205.58
- REXULTI (Drug) $185.24
- Wegovy (Drug) $172.27
- TRULICITY (Drug) $170.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in San Angelo
Peter Chang, Md, MD
Family Medicine — Payments: $16,020
Family Medicine $16,020
Dr. Warren Conway, Md, MD
Family Medicine — Payments: $13,830
Family Medicine $13,830
Brett Nile, Md, MD
Family Medicine — Payments: $12,206
Family Medicine $12,206
Viki Forlano, Md, MD
Family Medicine — Payments: $7,303
Family Medicine $7,303
Cornelius Chinn, Md, MD
Family Medicine — Payments: $5,963
Family Medicine $5,963
Winston Mcqueen Robalino, M.d, M.D
Family Medicine — Payments: $4,769
Family Medicine $4,769